Title
Category
Credits
Event date
Cost
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
This activity aims to explore best practices in cancer screening and shed light on the groundbreaking WISDOM Study, which is revolutionizing our approach to screening by testing a personalized precision-medicine method based on individual risk factors for breast cancer in contrast to traditional annual mammograms. Participants will learn how this alternative approach differs from the current “one-size-fits-all” guideline-based method and discuss its potential to significantly improve the effectiveness of screening.
  • Disease management
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 ADA - CERP (Dentists/Allied Dental Staff)
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CDR - Dietitians
  • 1.00 ASWB - Social Workers
$0.00
Alzheimer’s disease (AD) is a pressing public health crisis, affecting more than 6 million people in the U.S. and increasing in prevalence with the aging population. Join us in exploring the latest advances in AD diagnosis and management, including biomarkers, imaging techniques and cognitive assessments. Emerging pharmacological therapies that target the underlying disease and novel approaches to optimizing patient care will be highlighted.
  • Disease management
  • Oncology
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 CDR - Dietitians
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity discusses the current prevalence trends for CRC, new insight into risk factors, recommended screening approaches and modalities, treatment updates focused on tumor-specific molecular targets, and recent and emerging findings in CRC research and clinical trials.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of leukodystrophies, including current clinical trials. It will also share insights and perspectives from individuals and their family/caregiver(s) and provide strategies to support their well-being.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of Pompe disease and other LSDs, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s) and highlight the role of the interprofessional team in evaluating and improving care for patients with these conditions.
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 0.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore recent advances in the diagnosis and treatment of KLA and other lymphatic conditions, including current clinical trials. It will also share insights and perspectives from and provide strategies to support the well-being of both the individual and their family/caregiver(s).
  • Disease management
  • Health equity
  • Rare diseases
  • 1.00 ACPE - Pharmacists
  • 1.00 ACPE - Pharmacy Technicians
  • 1.00 AMA - Physicians
  • 1.00 ANCC - Nurses
  • 1.00 APA - Psychologists
  • 1.00 Attendance - General Attendance
  • 1.00 CCMC - General - Case Managers
  • 1.00 PRC-CPD - Philippine Professional Nursing
  • 1.00 ASWB - Social Workers
$0.00
This activity will explore the recent advances in the diagnosis and treatment of achondroplasia and other causes of disproportionate short stature. It will also share the importance of the interprofessional team to provide insights, perspectives and strategies to support the well-being of both the individual and their family/caregiver(s).
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will provide an overview of cardiovascular risk factors specific to women and explore the latest strategies and tools for assessing and mitigating these risks and improving overall cardiovascular care.
  • Disease management
  • 0.75 ACPE - Pharmacists
  • 0.75 ACPE - Pharmacy Technicians
  • 0.75 ADA - CERP (Dentists/Allied Dental Staff)
  • 0.75 AMA - Physicians
  • 0.75 ANCC - Nurses
  • 0.75 APA - Psychologists
  • 0.75 Attendance - General Attendance
  • 0.75 CDR - Dietitians
  • 0.75 ASWB - Social Workers
$0.00
This activity will address updates in evidence-based PM screening strategies, diagnosis, and treatment approaches. It will review the unique challenges faced by women in the perimenopausal stage and discuss the range of physical, emotional, and cognitive symptoms commonly experienced. Participants will be empowered to participate in shared decision-making through improved communication with patients experiencing PM.

Pages